About
Here you will find summaries of all the latest publications on lupus, focusing on those covering treatments, recommendations and other topics that may influence clinical practice.
Latest Updates
All ▼
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
Lupus patients given hope of remission in groundbreaking trial
UCB and Biogen announce positive Phase 3 results of dapirolizumab pegol in SLE from the PHOENYCS GO study
Lupus Therapy Essentials 2024 Update
World Kidney Day 2024
Researchers from Trinity College Dublin establish a link between fumarate hydratase and inflammatory macrophages, identifying a potential future treatment pathway for lupus.
Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial
Comparison of a voclosporin-based triple immunosuppressive therapy to high-dose glucocorticoid-based immunosuppressive therapy: A propensity analysis of the AURA-LV and AURORA 1 studies and ALMS
The 2024 APLAR consensus on the management of lupus nephritis
Association of lupus low disease activity state and remission with reduced organ damage and flare in systemic lupus erythematosus patients with high disease activity
Efficacy and safety of sodium-glucose co-transporter 2 inhibitors for the primary prevention of cardiovascular, renal events and safety outcomes in patients with systemic lupus erythematosus and comorbid type 2 diabetes: A population-based target trial emulation
Effect of iberdomide on cutaneous manifestations in systemic lupus erythematosus: a randomized phase 2 clinical trial
Attainment of EULAR/ERA-EDTA targets of therapy with current immunosuppressive regimens and adjustments in treatment: a multicentre, real-life observational study
Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first-in-patient, randomised, double-blind, phase I/II study in systemic lupus erythematosus
CD19-CAR T-cell therapy induces deep tissue depletion of B cells
Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for systemic lupus erythematosus: A Phase 2 randomized controlled trial
Urinary soluble CD163 is useful as "liquid biopsy" marker in lupus nephritis at both diagnosis and follow-up to predict impending flares
Immunosuppressives discontinuation after renal response in lupus nephritis: predictors of flares, time to withdrawal and long-term outcomes
Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study
Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study
Combination of anti-SSA/Ro60 and anti-dsDNA serotype is predictive of belimumab renal response in patients with lupus nephritis
Efficacy and safety of telitacicept therapy in systemic lupus erythematosus with hematological involvement
ANA-associated arthritis: clinical and biomarker characterization of a population for basket trials
Belimumab Corticosteroid‑Sparing Treatment in Systemic Lupus Erythematosus: a Real‑Life Observational Study (BESST)
SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort
Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two Phase 3 trials
TYK2: An emerging therapeutic target in rheumatic disease
Cardiovascular risk factors and complications in patients with systemic lupus erythematosus with and without nephritis: A systematic review and meta-analysis
Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: A multinational observational cohort study
Lupus low disease activity state and organ damage in relation to quality of life in systemic lupus erythematosus: A cohort study with up to 11 years of follow-up
CD19 CAR T-Cell therapy in autoimmune disease - A case series with follow-up
